Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access treatment protocol of SUTENT in imatinib-refractory or -intolerant GIST
2004-001860-27Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sunitinib in gastrointestinal stromal tumor (GIST), sponsored by Pfizer. Primary endpoints: Treatment access and Clinical endpoints (unspecified). Started Feb 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2004-001860-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001860-27.